In this study, we found that loss of PTEN increases NR2F1 expression and subsequently increases DNAI2 expression, leading to bronchial cell hyperplasia but inhibiting alveolar cell hyperplasia during EGFRL858R-induced lung cancer progression, a finding expected to be beneficial for the precision medicine in the treatment of lung cancer in the future (Fig. 7B). The gene discussed is DNAI2; the disease is lung cancer.